Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Imagion Biosystems Ltd. ( (AU:IBX) ) just unveiled an update.
Imagion Biosystems has released its quarterly activity report for Q1 FY2025, highlighting progress in its MagSense® HER2 breast cancer imaging agent program. The company is preparing to file an Investigational New Drug (IND) application with the U.S. FDA, which would enable the next phase of clinical studies. Manufacturing of the imaging agent is underway, and discussions with leading hospitals and cancer centers in the U.S. are ongoing. The company expects to file the IND in the third quarter and begin the Phase 2 study in the latter half of the year. Additionally, research and development for prostate and ovarian cancer programs are anticipated to commence later in the year, contingent on funding. The company reported a cash balance of AU$1.71 million at the end of March 2025, with increased operating cash outflows due to R&D expenditures.
More about Imagion Biosystems Ltd.
Imagion Biosystems is a company focused on developing non-radioactive, precision diagnostic molecular imaging technology. By integrating biotechnology and nanotechnology, the company aims to detect cancer and other diseases earlier and with greater specificity than currently possible.
YTD Price Performance: -35.00%
Average Trading Volume: 1,012,005
Technical Sentiment Signal: Buy
Current Market Cap: A$2.62M
For an in-depth examination of IBX stock, go to TipRanks’ Stock Analysis page.